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Abstract
Aims: The purpose of this study was to determine whether Nrf2 activation, via Keap1-knockdown (Keap1-KD),
regulates lipid metabolism and mobilization induced by food deprivation (e.g. fasting).
Methods and Results: Male C57BL/6 (WT) and Keap1-KD mice were either fed ad libitum or food deprived for 24
hours. After fasting, WT mice exhibited a marked increase in hepatic lipid accumulation, but Keap1-KD mice had an
attenuated increase of lipid accumulation, along with reduced expression of lipogenic genes (acetyl-coA carboxylase,
stearoyl-CoA desaturase-1, and fatty acid synthase) and reduced expression of genes related to fatty acid transport,
such as fatty acid translocase/CD36 (CD36) and Fatty acid transport protein (FATP) 2, which may attribute to the
reduced induction of Peroxisome proliferator-activated receptor (Ppar) α signaling in the liver. Additionally, enhanced
Nrf2 activity by Keap1-KD increased AMP-activated protein kinase (AMPK) phosphorylation in liver. In white adipose
tissue, enhanced Nrf2 activity did not change the lipolysis rate by fasting, but reduced expression of fatty acid
transporters — CD36 and FATP1, via a PPARα-dependent mechanism, which impaired fatty acid transport from
white adipose tissue to periphery circulation system, and resulted in increased white adipose tissue fatty acid
content. Moreover, enhanced Nrf2 activity increased glucose tolerance and Akt phosphorylation levels upon insulin
administration, suggesting Nrf2 signaling pathway plays a key role in regulating insulin signaling and enhanced
insulin sensitivity in skeletal muscle.
Conclusion: Enhanced Nrf2 activity via Keap1-KD decreased fasting-induced steatosis, pointing to an important
function of Nrf2 on lipid metabolism under the condition of nutrient deprivation.
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Introduction
The reported overall prevalence of obesity among adults
increased to 26.7% in 2009 from the Centers for Disease
Control and Prevention [1]. Obesity-associated insulin
resistance is a pathogenic event responsible for metabolic
syndrome, which comprises Type 2 Diabetes (T2D),
atherosclerosis, coronary heart disease and cancer, resulting in
increased morbidity and mortality. Weight loss is well known as
a useful strategy to prevent obesity in overweight or obese
person with T2D. It is controversial whether weight loss is
beneficial for reducing morbidity and mortality in individuals
with high risk of obesity and diabetes [2,3], but a decrease in
body weight is beneficial for the conversation of muscle energy
and activity, which is important for enhancing the quality of life.
Food deprivation/fasting or calorie restriction has been
demonstrated as a useful and efficient strategy to control body
weight.
Peroxisome proliferator activated receptor (Ppar) α signaling
mediates the response to fasting in mice [4]. Pparα is
expressed in tissues that have high rates of fatty acid oxidation,
including liver, kidney, heart, and brown adipose tissue [5]; as
well, white adipose tissue (WAT) [6]. Prolonged food
deprivation induces a dramatic change of energy utilization and
metabolism in mammalian model, via increasing the release of
fatty acids from WAT, and enhancing fatty acid oxidation in
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liver [4]; this results in rapid body fat mobilization, and
dramatically increases hepatic lipid accumulation [7]. Guan et
al. reported that mice undergoing 24 hours of fasting exhibited
excessive hepatic triglyceride (TG) accumulation and obvious
hepatic steatosis, further suggesting that prolonged food
deprivation induces dramatic energy mobilization and promotes
fatty liver development process [8].
Hepatic steatosis, also known as fatty liver disease, is a
reversible condition in which large vacuoles of TG or fat
accumulate in hepatocytes, characterized by accumulation of
lipid exceeding of 5% wet liver weight. Obesity, diabetes, and
hyperlipidemia are the most common co-existing conditions
frequently associated with fatty liver disease [9]. Upregulation
of fatty acid uptake is associated with increased hepatic lipid
accumulation, and results in hepatic steatosis [10]. Uptake of
un-esterified long chain fatty acid into hepatocytes or
adipocytes occurs through both a passive diffusion, and a
saturable, protein-mediated mechanism, and is regulated by
several membrane-associated proteins, including Fatty acid
translocase/CD36 (CD36), Fatty acid transport protein (FATP)
1 through 6, and plasma membrane-associated fatty acid
binding protein (FABPpm) [11]. Upregulation of CD36 was
determined to be significantly associated with hepatic steatosis,
hyperinsulinemia, and insulin resistance [12]. Deficiency of
FATP2 or FATP5 genes reduced hepatic steatosis in mice
[13,14], suggesting membrane-associated fatty acid transporter
proteins play a significant role in the development of fatty liver.
Nuclear factor erythoid 2-related factor 2 (Nrf2, Nfe2l2)
serves as a major regulator of a cellular defense system
against oxidative stress, resides in the cytoplasm, and is
sequestered by Kelch-like ECH-associated protein 1 (Keap1)
for targeted degradation by Cullin 3-base E3 ubiquitin ligase
[15]. Upon electrophilic/oxidative stress, the sequestration
complex dissociates, Nrf2 escapes from Keap1-mediated
repression and activates antioxidant-responsive element-
dependent gene expression associated with the cytoprotective
responses to a variety of drugs, toxicants, and cellular oxidative
stresses [16]. It was reported that Keap1-knockdown (Keap1-
KD, KD) mice exhibited enhanced Nrf2 signaling in liver [17].
However, the function of Nrf2 on lipid metabolism and fatty liver
is not well understood and contradictory conclusions exist in
the published literature. Enhanced Nrf2 activation (via Keap1-
KD) attenuated methionine- and choline-deficient diet-induced
fatty liver by increasing hepatic antioxidant and detoxification
capacity [18]. A global analysis of mouse hepatic gene
expression revealed that both genetic and pharmacologic
activation of Nrf2 resulted in induction of a larger number of
genes associated with lipid and glucose metabolism than
xenobiotic detoxification, and tended to decrease lipid
synthesis in the liver [19], suggesting that the presence of Nrf2
suppresses lipid metabolism. In contrast, Nrf2-null mice fed a
chronic high fat-diet (HFD) exhibited less hepatic lipid
accumulation and decreased hepatic steatosis, suggesting that
presence of Nrf2 increases hepatic lipid accumulation and
promotes the development of fatty liver in mouse model
[20,21].
To reveal the effects of enhanced Nrf2 activity in lipid
mobilization, WT and Keap1-KD mice were food-deprived for
24 hours to induce fatty liver, hepatic lipid accumulation and
gene expression related to lipogenesis and fatty acid transport
were determined. In livers of Keap1-KD mice, fasting-induced
steatosis was ameliorated, along with decreased lipogenic
gene expression and reduced induction of Pparα signaling,
which subsequently reduced fatty acid transporter protein
expression levels and the related fatty acid transport, indicating
that enhanced Nrf2 activity via Keap1-KD prevented fasting-
induced steatosis in mouse model.
Materials and Methods
Animals
Male 15- to 16-week-old C57BL/6 mice (WT) were
purchased from Charles River Laboratories (Wilmington, MA).
Keap1-KD mice were shared by Dr. Curtis Klaassen (University
of Kansas Medical Center, Kansas City, KS) and Dr. Masayuki
Yamamoto (Tohoku University Graduate School of Medicine,
Sendai, Japan). Mice were fed with Teklad Rodent Diet 7012
(Harlan, Madison, WI) and allowed access to water ad libitum
unless otherwise noted. All procedures were conducted in
accordance with the NIH Guidelines for the Care and Use of
Laboratory Animals and were approved by the University of
Rhode Island Animal Care and Use Committee.
Fasting Studies
Mice were divided into four groups: C57BL/6 fed ad libitum
(WT-Fed), C57BL/6 food withheld (WT-Fasted), Keap1-KD fed
ad libitum (KD-Fed), and Keap1-KD food withheld (KD-Fasted),
n=8 to 9 for each group. The day before fasting, mice were
housed singly and acclimated for one day. Next, mice were
allowed access to water and food ad libitum or water only.
Blood, liver, skeletal muscle (SKM) and the epididymal pad of
WAT were collected 24 hrs after food was withheld. Blood was
centrifuged at 5,000 x g for 15 mins at 4°C; serum was isolated
and stored at -80°C. Two portions of the left lobe of each liver
were ﬁxed in 10% formalin. Remaining liver was snap frozen in
liquid nitrogen and stored at -80°C.
Histopathology
Liver tissue was fixed in buffered formalin for 24 hrs, and
then processed for paraffin embedding. Paraffin sections (5
μm) were cut and stained with hematoxylin and eosin (H&E).
All procedures were performed according to typical histology
protocols as performed by AML Laboratories (Baltimore, MD).
For Oil Red O staining, frozen sections from liver were fixed
with 10% formalin for 10 mins, then incubated with Oil Red O
solution (six parts Oil Red O stock solution and four parts H2O;
Oil Red O stock solution is 0.5% Oil Red O in 100%
isopropanol) for 15 mins. Slides were counterstained with
hematoxylin and mounted in glycerin jelly.
Glucose Assay
Glucose levels in serum were analyzed using glucose assay
kit (Cayman Chemical Company, Ann Arbor, MI) according to
the manufacturer’s instruction. Five hundred microliters of
glucose assay reagent was added to 5 µl of standard or serum
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sample, and then incubated at 37°C for 10 mins. The
absorbance was measured at 500-520 nm by using a 96-well
plate reader.
Lipid Content Quantification
Liver or WAT (50 mg) were homogenized with PBS and
extracted with mixture of chloroform-methanol (2:1; v/v). The
residue was re-suspended in 1% Triton X-100 in 100% ethanol.
TG and free fatty acid (FFA) content were determined by using
TG (Pointe Scientific, Inc, MI,) and FFA (Wako Chemicals
USA, Inc, VA) reagent kits. Serum cholesterol content was
measured by using commercial cholesterol reagent kit (Pointe
Scientific, Inc, MI).
Serum Analytes
Serum insulin, resistin, IL-6, TNFα, and glucagon
concentration were determined by using a Millliplex MAP kit
(Millipore, MA) according to manufacturer’s instruction. Serum
glycerol content was determined by using a glycerol
colorimetric assay kit (Cayman Chemical Company, Ann Arbor,
MI). Serum β-hydroxybutyrate content was determined by
using a commercial kit purchased from Pointe Scientific, Inc
(Canton, MI).
RNA Isolation and Quantitative Real-Time PCR
Total RNA was isolated by using TRIzol reagent (Invitrogen,
CA) according to the manufacturer’s instruction. One
microgram of total RNA was converted to single-stranded
cDNA using oligo(d)T18 primers and mRNA levels were
quantiﬁed by quantitative real-time PCR using Roche
Lightcycler detection system (Roche Applied Science,
Mannheim, Germany). Samples were run by using SYBR
green and compared with levels of 18S rRNA or β-2
microglobulin as a reference housekeeping gene. PCR
conditions were optimized for each gene using appropriate
forward and reverse primers. The primers used are listed in
Table S1. All oligonucleotides were synthesized by Invitrogen
Inc., CA.
Western Blot Analyses
The samples (40 µg) were subjected to SDS-PAGE on 10%
polyacrylamide gels. Proteins were then electrophoretically
transferred to PVDF membrane. After transferring, the
membrane was blocked with 5% non-fat dry milk in TBS
Tween-20 followed by incubation with primary antibodies
overnight. The results were documented on X-ray ﬁlm by using
an ECL detection kit (GE Healthcare Life Science, Piscataway,
NJ). Primary antibodies were directed against: total-AMPKα,
AMPKα phosphorylated at Thr172, total-AMPKβ1/2, AMPKβ1
phosphorylated at Ser108, Acc-1, Scd-1, total-Akt, Akt
phosphorylated at Ser473 and GAPDH (Cell Signaling
Technology, Danvers, MA); and Glut4 (from Sigma-Aldrich, St.
Louis, MO).
Primary Hepatocyte Culture
Mouse hepatocytes were isolated using a two-step perfusion
as described previously [22]. Cells were isolated from 2-3
month-old male C57BL/6 and KD mouse, 1×106 cells/well in 2
mL completed medium (MEM supplied with 10% FBS) were
seeded on collagen-coated 6-well plates. After cells attachment
(~4 hrs), they were cultured in serum-free MEM containing 1%
ITS supplement (Invitrogen, CA). Twenty-four hours post
plating, hepatocytes were harvested and the total protein was
collected for the next measurement.
VLDL Secretion Measurement
Male mice (8-week-old) fasted for 5 hrs were injected with
Tyloxapol (Triton WR-1339, Sigma-Aldrich, St. Louis, MO) (0.5
mg/g body weight) in a 0.9% NaCl solution via tail vein. Blood
samples were collected at 0, 60, and 120 mins after injection.
Serum TG content was measured as before.
Exogenous Lipid Clearance Rate Measurement
Male mice (8-week-old) were fasted overnight (>16 hrs) and
then administered with olive oil via oral gavage (15 ml/kg body
weight, Sigma-Aldrich, St. Louis, MO). Blood samples were
collected at 0, 1, 3, and 6 hrs after oil administration. Serum
was extracted and TG content was measured as before.
GTT and ITT Assay
Glucose tolerance test (GTT) or insulin tolerance test (ITT)
were performed by i.p. injecting glucose (1 g/kg) or insulin (1
U/kg) in WT and Keap1-KD mice fasted for 16 or 6 hrs. Blood
glucose was determined by tail nick bleeds at 0, 30, 60, 90,
120, and 150 mins post glucose administration or 0, 15, 30, 60,
and 120 mins post insulin administration.
Acute Insulin Treatment in Mice
Acute insulin treatment was performed as described
previously [23]. Male 15-week-old mice fasted overnight (>16
hrs) were anesthetized and a maximal bolus of insulin (5 U/kg
body weight; Sigma-Aldrich, St. Louis, MO) was injected into
the portal vein. Gastrocnemius muscles were collected 5 mins
after the injection and immediately stored in liquid nitrogen.
Protein extracts from the tissue samples were prepared and
run on SDS-PAGE.
Statistical Analysis
Quantitative data were presented as mean ± S.E. Statistic
differences were determined by a one-way ANOVA followed by
a Duncan’s Multiple Range post hoc test. All statistical tests
with P<0.05 were considered as significant.
Results
Enhanced Nrf2 activity prevents fasting effects in
Keap1-KD mice
After fasting for 24 hrs, WT and Keap1-KD mice lost a
substantial amount of total body weight (10.5% and 9.8%,
respectively), liver weight (14.6% and 27.5%, respectively), and
epididymal WAT weight (32.5% and 12.9%, respectively)
(Table 1). Glucagon was not detectable in Keap1-KD mice in
fed or fasted state. Resistin levels were deceased by 40.7%
and 42.5%, and IL-6 levels were decreased by 66.1% and
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62.1% in WT and Keap1-KD mice after fasting, respectively.
TNFα levels were decreased to non-detectable concentrations
after fasting in WT and Keap1-KD mice (Table S2). Serum
glucose content was similar between WT and Keap1-KD mice
in fed state. However, fasting reduced glucose content by
36.2% in WT mice, but only 15.2% in Keap1-KD mice (Figure
1A). Insulin content was decreased by 77.5% in WT mice,
however only 20.8% in Keap1-KD mice (Figure 1B). β-
hydroxybutyrate content was increased by 614% in WT mice
after fasting, but only 380% induction was determined in
Keap1-KD mice (Figure 1C), which suggested Keap1-KD
interfered with fasting effects. Furthermore, serum TG content
was similar among the four experimental groups (Figure 1D).
FFA content was increased by 115% in WT mice, but only
60.6% increase was observed in Keap1-KD mice, and Keap1-
KD mice exhibited lower FFA content compared with WT mice
(Figure 1E). Cholesterol content was decreased in WT mice
(by 19.5%), and no significant decrease was observed in
Keap1-KD mice after fasting (Figure 1F).
Enhanced Nrf2 activity prevents fasting-induced fatty
liver in Keap1-KD mice
No inflammation was observed in livers of fed or fasted WT
and Keap1-KD mice (Figure S1). Oil Red O staining was
performed to identify lipid content in liver. No obvious Oil Red
O staining was observed in WT and Keap1-KD mice in fed
state. The staining dramatically increased after fasting in WT
mice, but the increase was attenuated in Keap1-KD mice, as
noted by decreased Oil Red O staining in Keap1-KD mice
compared with WT mice (Figure 2A). Lipids were also
extracted from liver tissue and the content was quantified by
spectrometer method. Hepatic TG and FFA content increased
robustly in WT mice after fasting (362% and 79.7%,
respectively), but the increase was attenuated in Keap1-KD
mice (only 162% and 37.8%, respectively), suggesting
enhanced Nrf2 activity prevented fasting-induced fatty liver
(Figure 2B and 2C). In fed and fasted states, WT and Keap1-
Table 1. Body weight, liver weight and epididymal white
adipose tissue weight of C57BL/6 and Keap1-KD mice after
24 hours fasting.
 C57BL/6 Keap1-KD
 Fed Fasted Fed Fasted
Body Weight(BW), g 27.70±0.46 24.79±0.66* 27.56±0.62 24.85±0.76#
Liver Weight(LW), g 1.23±0.04 1.05±0.03* 1.42±0.08$ 1.03±0.04#
LW/BW, % 4.44±0.09 4.25±0.06 5.11±0.19$ 4.15±0.13#
Epididymal WAT Weight
(EW), g 0.40±0.07 0.27±0.06 0.85±0.17
$ 0.74±0.11§
EW/BW, % 1.39±0.27 1.09±0.23 2.80±0.51$ 2.78±0.32§
Fifteen- to sixteen-week-old C57BL/6 (WT) and Keap1-KD (KD) mice were food
withhold for 24 hrs, then were anesthetized and the organ weight was measured. *
P<0.05, WT-Fasted compared with WT-Fed mice; $, P<0.05, KD-Fed compared
with WT-Fed mice; # P<0.05, KD-Fasted compared with KD-Fed mice; § P<0.05,
KD-Fasted compared with WT-Fasted mice.
doi: 10.1371/journal.pone.0079841.t001
KD mice had comparable levels of hepatic cholesterol (Figure
2D).
Enhanced Nrf2 activity attenuates Pparα signaling
induction and decreases lipogenic gene expression in
liver by fasting
Keap1 mRNA levels was decreased by 47.1% and 62.4% in
fed and fasted Keap1-KD mice as compared with WT mice,
respectively. NAD(P)H:quinone oxidoreductase 1 (Nqo1), a
target gene of Nrf2 signaling [24], was induced in Keap1-KD
mice, suggesting Nrf2 signaling activation in this genotype. No
significant difference of Pparα mRNA levels was observed
between WT and Keap1-KD mice in fed and fasted states.
However, the expression of Cyp4a14 and Carnitine
palmitoyltransferase (CPT) 1a, two target genes of Pparα
signaling [25,26], were markedly induced in WT mice after
fasting, but were attenuated in Keap1-KD mice. Furthermore,
Pparα protein levels were induced by fasting in WT mice, but
Figure 1.  Enhanced Nrf2 activity prevents fasting effects
in Keap1-KD mice.  Serum content of (A) glucose, (B) insulin,
(C) β-hydroxybutyrate, (D) TG, (E) FFA, and (F) cholesterol
were determined in fed and fasted C57BL/6 (WT) and Keap1-
KD (KD) mice (n=4-9 per group). *, P<0.05, WT-Fasted
compared with WT-Fed mice; #, P<0.05, KD-Fasted compared
with KD-Fed mice; §, P<0.05, KD-Fasted compared with WT-
Fasted mice.
doi: 10.1371/journal.pone.0079841.g001
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this induction was blocked completely in Keap1-KD mice
(Figure 3B). The protein levels in Keap1-KD mice were
significantly decreased compared with WT mice (Figure 3C),
suggesting that enhanced Nrf2 activation (via Keap1-KD) may
impair fasting-induced induction of Pparα signaling in Keap1-
KD mice (Figure 3A). Lipogenic gene expression was
determined by quantitative real-time PCR to explore Nrf2
function on de novo lipogenesis. Fatty acid synthase (Fas),
Acetyl-CoA carboxylase (Acc) 1, and Stearoyl-CoA
desaturase-1 (Scd1) were decreased by fasting in WT mice,
and Keap1-KD mice exhibited an even greater decrease,
suggesting enhanced Nrf2 activity promoted fasting-induced
lipogenic gene reduction. The current study suggests that
Keap1-KD may reduce lipogenesis and lipid accumulation by
inhibiting lipogenic gene expression in liver (Figure 3D).
Enhanced Nrf2 activity increases AMPKα
phosphorylation in liver of Keap1-KD mice
Figure 4A illustrates that, from protein levels, the expression
of hepatic lipogenic genes, Acc1 and Scd1, was decreased in
Figure 2.  Enhanced Nrf2 activity prevents fasting-induced fatty liver in Keap1-KD mice.  (A) Representative images of Oil
Red O staining of livers sections in fed and fasted C57BL/6 (WT) and Keap1-KD (KD) mice. Magnification: 200×. Scale bar=50 μm
(n=3 per group). Hepatic (B) TG, (C) FFA, and (D) cholesterol from fed and fasted C57BL/6 (WT) and Keap1-KD (KD) mice (n=4-6
per group). *, P<0.05, WT-Fasted compared with WT-Fed mice; #, P<0.05, KD-Fasted compared with KD-Fed mice; §, P<0.05, KD-
Fasted compared with WT-Fasted mice.
doi: 10.1371/journal.pone.0079841.g002
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Figure 3.  Enhanced Nrf2 activity attenuates Pparα signaling induction and decreases lipogenic gene expression in liver by
fasting.  (A) The induction of Cyp4a14 and CPT 1a by fasting was attenuated in liver of Keap1-KD (KD) mice. (B, C) Immunoblot
analysis of Pparα in liver from fed or fasted C57BL/6 (WT) and Keap1-KD (KD) mice. (D)The expression of lipogenic genes, such as
Fas, Acc1, and Scd1, was decreased in liver of Keap1-KD (KD) mice compared to C57BL/6 (WT) mice by fasting (n=4-6 per group).
*, P<0.05, WT-Fasted compared with WT-Fed mice; #, P<0.05, KD-Fasted compared with KD-Fed mice; §, P<0.05, KD-Fasted
compared with WT-Fasted mice.
doi: 10.1371/journal.pone.0079841.g003
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Keap1-KD mice by fasting than WT mice, which is in
agreement with the previous observation (Figure 3B).
Phosphorylated-Acc was slightly increased in Keap1-KD mice
than WT mice in fasted state (P=0.058). In order to explore the
mechanism by which Nrf2 activation regulates lipogenic gene
expression, AMPK signaling activation was evaluated by
western blot. Fasting increased p-AMPKα levels in WT mice,
which is also seen in the previous study [27]. Nrf2 significantly
increased p-AMPKα levels in Keap1-KD mice in fed and fasted
states than WT mice. There was no significant difference of p-
AMPKβ1 and p-AMPKβ1/AMPKβ1/2 in fed and fasted WT and
Keap1-KD mice (Figure 4B). Additionally, increased p-AMPKα
levels were observed in primary hepatocytes isolated from
Keap1-KD mice (Figure 4C), further suggesting Nrf2 activated
AMPKα signaling, which may repress lipogenic gene
expression (such as Acc1) in liver (Figure 3B).
Enhanced Nrf2 activity decreases serum lipid clearance
rate and VLDL secretion in Keap1-KD mice
Lipid transport is associated with lipid accumulation [28]. In
order to determine whether lipid transport alteration contributes
to the observed reduction of hepatic lipid accumulation in
Keap1-KD mice, WT and Keap1-KD mice were administered
with exogenous lipids, and the lipid clearance rate was
determined. Figure 5A illustrates that Keap1-KD mice exhibited
higher content of serum TG than WT mice at 1 and 6 hrs after
oil administration, even though these mice had lower TG
content at time 0, suggesting enhanced Nrf2 activity decreased
the exogenous lipid clearance rate. In order to explore which
molecular mechanism was involved, the mRNA levels of
hepatic CD36, FATP2, FATP5, and FABPpm, the membrane-
associated transporter protein, were determined. CD36 and
FATP2 mRNA levels were significantly induced in WT mice
after fasting, but the induction was attenuated in Keap1-KD
mice (Figure 5B). FATP5 and FABPpm mRNA levels were
similar in WT and Keap1-KD mice in fed and fasted states
(Figure 5B). The current data suggest that enhanced Nrf2
activity inhibited fatty acid transporter expression, which could
explain the impaired fatty acid transport to the liver and
reduced hepatic lipid accumulation. Additionally, hepatic
VLDL/TG secretion was determined in fasted WT and Keap1-
KD mice. Figure 5C and 5D illustrate that WT mice had higher
hepatic VLDL secretion rate than Keap1-KD mice.
Apolipoprotein B (ApoB) and Microsomal triglyceride transfer
protein (MTTP), the two genes responsible for hepatic VLDL
assembly and secretion, were significantly induced in WT mice
by fasting, but the induction was attenuated in Keap1-KD mice,
further suggesting enhanced Nrf2 activity decreased VLDL
secretion from the liver (Figure 5E and 5F). Reduced VLDL
secretion was associated with increased hepatic steatosis [29],
but Keap1-KD mice exhibited decreased hepatic lipid content
with repaired VLDL secretion. It is possible that this effect was
overwhelmed by others, such as the attenuated hepatic
lipogenesis or fatty acid uptake.
Enhanced Nrf2 activity decreases fatty acid transport
and results in increased fatty acids content in white
adipose tissue
TG content in WAT was increased in WT and Keap1-KD
mice, but no significant difference was observed between these
two genotypes in fed and fasted states (Figure 6A). Food
deprivation is known to decrease serum insulin content, which
induces lipolysis in WAT, and increases release of FFA and
glycerol to peripheral circulatory system [30]. FFA content was
decreased by 28% in WAT from WT mice, but the decrease
was completely blocked in Keap1-KD mice (Figure 6B). Fasting
induced serum glycerol content by 20.0% and 17.2% in WT
and Keap1-KD mice, respectively. However, Keap1-KD mice
exhibited higher content of serum glycerol than WT mice in fed
and fasted states (Figure 6C). No significant difference of
lipase expression was observed in WT and Keap1-KD mice in
fed and fasted states, excluding Adipose triglyceride lipase
(ATGL), which was induced by fasting in WT mice (Figure S2).
Fasting is known to increase lipolysis and FFA export from
WAT, which reduces FFA content inside of adipocytes (Figure
6B). However, it was hypothesized that in Keap1-KD mice,
enhanced Nrf2 activity may impair the fatty acid transport out of
the WAT. Next, it was determined whether the expression of
fatty acid transporter protein was modulated by Nrf2 activation.
The mRNA levels of CD36, FATP1 and FATP4, and FABPpm,
which are predominantly expressed in WAT, were determined
by quantitative real-time PCR in WT and Keap1-KD mice.
Keap1 mRNA levels were decreased in WAT of Keap1-KD
mice (about 67.2% and 55.5% compared with WT mice in fed
and fasted states, respectively), which was associated with
increased Nqo1 mRNA levels (Figure 6D). CD36, FATP1,
FATP4 and FABPpm mRNA levels were significantly induced
in WAT of WT mice after fasting, but this induction was
attenuated in Keap1-KD mice (Figure 6E), suggesting Nrf2
activation via Keap1-KD inhibited fatty acid transport related
gene expression, perhaps impairing fatty acid transport out of
WAT and resulting in increased lipid accumulation within the
adipocytes. Fasting induced Pparα mRNA expression along
with the target gene, cytochrome c oxidase subunit IV (COXIV)
[31], but this induction was completely blocked in Keap1-KD
mice, as denoted by the reduced expression of Pparα and
COXIV. Additionally, induction of PGC1α, which plays an
important role in mediating fasting effects [32], was completely
blocked in Keap1-KD mice (Figure 6F). Furthermore, FATP1
protein levels were significantly induced by fasting in WT mice,
with no significant difference in Pparα signaling observed
between WT and Keap1-KD mice; however, there is a
significant decrease in Keap1-KD mice compared with WT
mice in fasted state (Figure 6G-I).
Enhanced Nrf2 activity increases glucose tolerance and
Akt phosphorylation in SKM upon insulin challenge
Imbalance of fatty acid transport is associated with insulin
resistance [33]. WT and Keap1-KD mice at normal
physiological condition were challenged with glucose and
insulin to detect insulin signaling status. Previously it was
reported that aged Keap1-KD mice exhibited comparable
glucose tolerance to corresponding C57BL/6 controls [34].
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However, reports do not exist regarding whether there is any
effect of Keap1-KD on glucose metabolism in young adult mice
under normal physiological conditions. Figure 7A illustrates that
Keap1-KD mice exhibited a lower glucose load than WT mice
Figure 4.  Enhanced Nrf2 activity increases AMPKα phosphorylation in liver of Keap1-KD mice.  Immunoblot analysis of (A)
Acc-1, Scd-1, and (B) total and p-AMPKα, total-AMPKβ1/2, and p-AMPKβ1 in livers of C57BL/6 (WT) and Keap1-KD (KD) mice. *,
P<0.05, WT-Fasted compared with WT-Fed mice; #, P<0.05, KD-Fasted compared with KD-Fed mice; §, P<0.05, KD-Fasted
compared with WT-Fasted mice. (C) p-AMPKα levels were increased in primary hepatocytes isolated from C57BL/6 (WT) and
Keap1-KD (KD) mice. &, P<0.05, KD compared with WT mice hepatocytes.
doi: 10.1371/journal.pone.0079841.g004
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Figure 5.  Enhanced Nrf2 activity decreases lipid clearance rate and VLDL secretion in Keap1-KD mice.  (A) Enhanced Nrf2
activity impairs lipid clearance. Ten-week-old C57BL/6 (WT) and Keap1-KD (KD) mice were fasted overnight (more than 16 hrs),
and then administered olive oil (15ml/kg) by oral gavage, serum TG content was measured 0, 1, 3, and 6 hrs after oil administration
(n=5 to 8 per group) (&, P<0.05, Keap1-KD compared with WT mice). (B) The expression of fatty acid transporters of CD36 and
FATP2 was deceased in liver from Keap1-KD mice compared with WT mice by fasting (n=4 to 6 per group). VLDL secretion was
impaired in Keap1-KD mice (C and D). Ten-week-old C57BL/6 (WT) and Keap1-KD (KD) fasted for 5 hrs were injected with
Tyloxapol (0.5 mg/g) and serum TG content was measured at 0, 1, and 2 hrs after injection (n=5 to 8 per group) (&, P<0.05, Keap1-
KD compared with WT mice). The induction of (E) ApoB and (F) MTTP expression was attenuated in liver of Keap1-KD mice by
fasting. The relative mRNA levels were quantified by quantitative real-time PCR and normalized with 18S as loading control (n=4-6
per group). *, P<0.05, WT-Fasted compared with WT-Fed mice; #, P<0.05, KD-Fasted compared with KD-Fed mice; §, P<0.05, KD-
Fasted compared with WT-Fasted mice.
doi: 10.1371/journal.pone.0079841.g005
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after acute glucose challenge, suggesting higher glucose
tolerance in Keap1-KD mice. An AUCGTT assay further
confirmed this observation (Figure 7B). No difference of insulin
tolerance was detected between WT and Keap1-KD mice
(Figure S3). In SKM, Keap1 mRNA levels were decreased by
43% in Keap1-KD mice, and Nqo1 mRNA levels were
increased, suggesting Nrf2 signaling was activated in Keap1-
KD mice. The mRNA levels of Pparγ, Sterol regulatory element
binding protein 1c (Srebp1c), and Insulin receptor (Insr), which
are associated with insulin signaling, were increased in Keap1-
KD mice, suggesting that enhanced Nrf2 activity increased
insulin signaling in SKM of mice. No significant difference of
Glut4 protein levels was detected from western blot (Figure
7D). Next, WT and Keap1-KD mice were challenged with
insulin to explore the response to insulin by the modulation of
enhanced Nrf2 activity. No difference of total-Akt was observed
between WT and Keap1-KD mice, but the phosphorylated-Akt
levels were increased in Keap1-KD mice (Figure 7E),
Figure 6.  Enhanced Nrf2 activity decreases fatty acid transport and results in increased fatty acids content in white
adipose tissue.  (A) TG and (B) FFA content were measured in white adipose tissue of fed and fasted C57BL/6 (WT) and Keap1-
KD (KD) mice (n=5-6 per group). (C) Nrf2 increased serum glycerol contents in Keap1-KD mice. (D, E, F) The induction of Pparα
signaling and fatty acid transporter expression by fasting was attenuated in white adipose tissue of Keap1-KD mice. Total RNA was
isolated from fed or fasted C57BL/6 (WT) and Keap1-KD (KD) mice and the relative mRNA levels were quantified by quantitative
real-time PCR and normalized with β-2 microglobulin as loading control (n=4-6 per group). (G, H, I) Immunoblot analysis of Pparα
and FATP1 in white adipose tissue from fed or fasted C57BL/6 (WT) and Keap1-KD (KD) mice. *, P<0.05, WT-Fasted compared
with WT-Fed mice; $, P<0.05, KD-Fed compared with WT-Fed mice; #, P<0.05, KD-Fasted compared with KD-Fed mice; §, P<0.05,
KD-Fasted compared with WT-Fasted mice.
doi: 10.1371/journal.pone.0079841.g006
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suggesting enhanced Nrf2 activity increased insulin signaling in
SKM upon insulin challenge.
Discussion
The current study began with the observation that Keap1-KD
mice exhibited a dramatic difference in their susceptibility to the
stimulus of fasting – with increased serum glucose and insulin
levels, reduced fasting-induced hepatic steatosis, and
decreased epididymal WAT weight loss compared with controls
(Table 1). Enhanced Nrf2 activity reduced fasting-mediated
induction of Pparα signaling in liver and WAT, decreased
hepatic de novo lipogenic gene expression of Fas, Acc1 and
Scd1, and reduced gene expression related to fatty acid
transport in liver and WAT. Enhanced Nrf2 activity promoted
glucose tolerance via increased Akt phosphorylation levels,
and increased the response upon insulin administration in
SKM. It was reported that pharmacologically-enhanced Nrf2
activity by Oltipraz prevented insulin resistance and attenuated
the HFD effect on glucose disposal, and reduced HFD-induced
obesity [35], further demonstrated that Nrf2 played negative
roles in the regulation of lipid metabolism.
Genetically-enhanced Nrf2 activity by Keap1-KD prevented
fasting-induced hepatic steatosis in mouse liver. Contradictory
reports exist regarding the role of Nrf2 function on regulation of
hepatic steatosis. Post 5 days of methionine- and choline-
deficient diet, WT mice showed higher hepatic lipid
accumulation as evidence by the increased hepatic fatty acid
uptake and reduced VLDL secretion [29]. Nrf2-null mice
exhibited more severe hepatic steatosis, while Keap1-KD mice
exhibited less, along with decreased CD36 and Fgf21
expression, suggesting Nrf2 negatively regulate lipogenesis
and hepatic lipid accumulation [18]. Moreover, mice
administered with oleanolic triterpenoid 1-[2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oyl] imidazole (CDDO-Im), a
potent Nrf2 activator, for 21 or 95 days, displayed protection
against HFD-induced body weight gain and WAT mass
increasing, along with decreased hepatic lipid accumulation.
However, this observation was not observed in Nrf2-null mice,
suggesting CDDO-Im prevented obesity and hepatic lipid
accumulation via an Nrf2-dependent mechanism [36].
Additionally, upon 4 weeks of HFD-treatment, Nrf2-null mice
exhibited increased expression of lipogenic genes and
transcription factors, such as Srebp1c and 2, Fas, and Acc1,
and increased hepatic FFA content, further demonstrated that
Nrf2 negatively regulate hepatic lipid accumulation [37]. It was
noted that the research work from Pi et al. [21] and
Chartoumpekis et al. [38], which reported that Nrf2-null mice
were somehow protected against HFD-induced obesity and
fatty liver for long-term treatment (12 and 24 weeks,
respectively). Our previous work reported Keap1-KD mice had
less lipid accumulation in WAT upon short-term HFD-treatment
(5 weeks) [24], and exhibited higher hepatic lipid accumulation
for long-term treatment (24 weeks) [34], suggesting Nrf2 may
play dual roles in regulating lipid accumulation regarding
different durations of high lipid loading. In the different models
explored, the interactions between diet (low or high fat diet),
length of time on diet, and intact hormonal axis (leptin
presence) must be considered. In models of Nrf2 activation,
consideration must be given to off-target effects that could be
beneficial or perhaps interact with the Nrf2 pathway and
Keap1. Overall, for future studies, an integrate body of work
that compares WT, Keap1-KD, and Nrf2-null mice treated with
short- and long-term HFD-intervention should be considered to
help advance the field.
Hepatic lipid accumulation is derived from: 1) de novo lipid
synthesis from fatty acids in the liver (lipogenesis); 2) uptake of
circulating albumin-bound fatty acids; and 3) uptake of
circulating VLDL and chylomicron lipid particles [39]. Fasting is
described to decrease lipogenesis and inhibit lipogenic gene
expression of Srebp1c, Acc1, and Fas in liver [40]. Decreased
expression of Fas, Acc1, and Scd1 have been reported in
association with reduced hepatic lipid accumulation in mouse
liver [37]. The current study demonstrated that increased Nrf2
activity in Keap1-KD mice decreased lipogenic gene
expression of Fas, Acc1, and Scd1 (Figure 3), which
contributed to the decreased fasting-induced hepatic steatosis
and lipid accumulation.
Another likely source of excess lipid for hepatic steatosis is
the increased influx of FFAs. It has been reported that various
membrane-associated fatty acid-binding proteins were
associated with the transport of cellular fatty acids in intestine,
liver, WAT, SKM and heart. The most characterized of these
are CD36, long-chain fatty acyl-CoA synthetases, and fatty acid
transport proteins 1 through 6 [11]. CD36 is ubiquitously
expressed in liver, heart, adipose tissue, and intestine [41].
FATP1 is the most prominent one in WAT, FATP2 is almost
exclusively expressed in liver and kidney [11]. Expression of
FATP4 was increased in human adipose tissue with obesity
[42]. Expression of FATP5 was reported in liver exclusively
[43]. FABPpm protein has been identified in liver [44], and WAT
[45]. Hepatic steatosis is associated with enhanced expression
of CD36 in patients with non-alcoholic steatohepatitis [12].
Also, hepatic steatosis induced by HFD significantly increased
CD36 expression, and forced expression of hepatic CD36 in
lean mice was reported to increase hepatic fatty acid uptake
and TG storage, further supporting the observation of hepatic
exiting in diet-induced-obesity mice [46]. It was reported that
FATP2 overexpression increased fatty acids uptake in human
hepatoma cells, suggesting FATP2 may play a key role in
regulating fatty acid uptake and subsequent cellular lipid
accumulation [47]. There is no significant difference in FATP5
or FABPpm expression between WT-fasted and KD-fasted
groups, a possible reason being that these two genes are
expressed to a relatively lesser degree than CD36 and FATP2
in liver.
It has been well summarized that PPAR/RXR signaling
pathway regulates FATP expression and hepatic lipid
accumulation [48]. Studies in mice demonstrated that Pparα
signaling regulated the gene expression related to lipid
metabolism in liver, including mitochondria and peroxisomal
fatty acid oxidation, fatty acid uptake, utilization and
catabolism, lipoprotein assembly and transport [49–51].
Fibrates, known as Pparα activators, induce FATP mRNA
levels and increase fatty acid uptake into liver [52]. Additionally,
Wy14,643 (Pparα activator), induced fatty acid transport related
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Figure 7.  Enhanced Nrf2 activity increases glucose tolerance and Akt phosphorylation upon insulin challenge.  (A and B)
Keap1-KD mice have a lower glucose load. Ten-week-old C57BL/6 (WT) and Keap1-KD (KD) mice fasted overnight were challenge
with glucose (2g/kg) and blood glucose levels were determined at 0, 30, 60, 90, 120, 150 mins after glucose administration (n=6 per
group) (*, P<0.05, Keap1-KD compared with WT mice). (C) Gene expression in skeletal muscle from C57BL/6 (WT) and Keap1-KD
(KD) at 16-week-old age. The relative mRNA levels were quantified by quantitative real-time PCR and normalized with 18S as
loading control (n=5 to 6 per group) (*, P<0.05, Keap1-KD compared with WT mice). (D) Immunoblot analysis of Glut4 in skeletal
muscle of C57BL/6 (WT) and Keap1-KD (KD) mice at 16-week-old age. GAPDH was used as loading control. (E) Enhanced Nrf2
activity increased p-Akt levels upon insulin administration in skeletal muscle. Fifteen-week-old C57BL/6 (WT) and Keap1-KD (KD)
mice fasted for 6 hrs were injected with a maximal bolus of insulin (5 U/kg) via portal vein. Five minutes later, gastrocnemius
muscles were removed and snap frozen in lipid nitrogen. &, P<0.05 as indicated.
doi: 10.1371/journal.pone.0079841.g007
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genes, but the induction was blocked in Pparα-null mice,
suggesting the induction was via a Pparα-dependent
mechanism [53]. In the current study, enhanced Nrf2 activity
impaired the fasting effects, and decreased Pparα signaling
activation, described by the attenuated induction of Pparα
protein levels, and the two target genes of Cyp4a14 and Cpt 1a
(Figure 3A), contributing to decreased gene expression related
to fatty acid transport and impair fatty acid influx to the liver in
Keap1-KD mice.
During fasting, serum glucose and insulin levels decrease
and glucagon levels increase, which results in an enhanced
WAT lipolysis rate to stimulate the breakdown of fat stored in
adipose tissue and subsequent release of fatty acids and
glycerol as fuel. Glycerol content increased similarly in WT and
Keap1-KD mice by fasting (Figure 6C), but was higher in
Keap1-KD mice than WT mice in fed and fasted states,
respectively. A possible reason is that Keap1-KD mice have a
greater amount of WAT than WT mice, which would increase
the lipolysis rate for the tissue and release more FFA into the
blood (Table 1). There is an increase of TG content in WAT
with fasting in WT and KD mice, which is consistent with our
previous work and the published literature [24] [54], the
possible reason is that fasting remove water from the tissue,
which will increase the relative weight of lipid content. But there
is no significant difference of TG content between these two
phenotypes after fasting, this may be due to the comparable
expression levels of lipase, such as Hormone-sensitive lipase
(Hsl), ATGL, and Monoacylglycerol Lipase (MGL), which are
important for TG breakdown in WAT (Figure S2). Food
deprivation induced Pparα signaling, accompanied by
increased PGC1α expression (Figure 6F), followed by
enhanced expression of genes related to fatty acid transport,
such as CD36, FATP1, FATP4, and FABPpm in WT mice,
which reduced lipid content inside of WAT (Figure 6B).
However, the expression of membrane-associated protein
responsible for fatty acid transport was attenuated in Keap1-KD
mice, which may impair fatty acid transport outside of
adipocytes, resulting in enhanced fatty acids content inside of
WAT.
It was noted that enhanced Nrf2 activity induced AMPK
activation in the liver (Figure 4). AMPK exists as a
heterotrimeric complex consisting of a catalytic subunit α and
two regulatory subunits β and γ involved in heterotrimer
formation and ligand sensing [55]. The conversational activity
of serine/threonine kinase activity of AMPK is supported by α
subunit. AMPK has been identified as a key regulator of energy
status and play key role in protecting against energy-restricted
conditions, such as food deprivation and caloric restriction in
the liver [56]. It has been demonstrated that during fasting-
feeding transition, AMPK is activated in the liver and
contributes to the switch between lipogenesis and β-oxidation
as a result of its energy sensor function [57]. Acc1 is an
important rate-controlling enzyme for the synthesis of malonyl-
CoA, which is important for de novo fatty acid synthesis in the
liver. Inhibition of Acc1 by AMPK leads to a fall in malonyl-CoA
content and a subsequent decrease in fatty acid synthesis, and
results in decreased lipid accumulation in the liver.
Glucose metabolism is closely related to lipid metabolism.
Mice with impaired glucose tolerance exhibited higher hepatic
lipid accumulation and more severe hepatic steatosis [58].
Enhanced Nrf2 activity increased glucose tolerance and insulin
sensitivity (Figure 7). It was reported previously that Keap1-KD
mice had comparable glucose tolerance to WT mice, which is
different from the current study. A possible reason is that older
mice were used (27 weeks) than in the current study (12
weeks). In addition, the previous study failed to use a sample
size large enough to have sufficient statistical power (4~5 vs
8~9) [34]. Pparγ and Srebp1c, which are important transcription
factor that mediated insulin function on glucose transport
[59,60], were increased in Keap1-KD mice. Thiazolidinediones,
known as Pparγ activators, are typically used as insulin
sensitizers and therapeutically used in the treatment of T2D
[61]. Insulin increased the mRNA levels of Glut4 by enhancing
Srebp1c mRNA levels and the recruitment of Srebp1c to the
putative sterol-response element in Glut4 promoter [62]. Glut4
is the membrane-associated protein and a major mediator of
glucose removal from circulation to cells [63]. No significant
difference of Glut4 protein content was observed between WT
and Keap1-KD mice, suggesting the increased glucose
tolerance in Keap1-KD mice may be not only determined by the
modulation of Glut4 expression, but Glut4 translocation may
play important roles in the current study. Activation of insulin
signaling induced Akt phosphorylation, which promotes Glut4
translocation from cell surface to plasma membrane and
increases glucose transport. In the current study, Keap1-KD
mice exhibited higher p-Akt upon insulin administration,
suggesting that Nrf2 promotes the insulin response, and finally
enhances Glut4 translocation to facilitate glucose transport into
cells. An ITT shows the ability of insulin-induced glucose
removal, thus it was surprising that there was no difference in
ITT between WT and KD mice. Our unpublished data
demonstrated that enhanced Nrf2 activity by Keap1-KD can
increase glucose production, suggesting this could compensate
for the removal of glucose upon insulin administration in
Keap1-KD mice.
Overall, the current study reports enhanced Nrf2 activity,
genetically via Keap1-KD, prevented fasting-induced fatty liver
by inhibiting fatty acid transport and impairing activation of the
Pparα signaling pathway in liver. Enhanced Nrf2 activity did not
change the lipolysis rate in WAT, but inhibited gene expression
related to fatty acid transport, which impaired fatty acid
transportation from WAT and increased fatty acid content
inside of the tissue. Also, enhanced Nrf2 activity increased
AMPK phosphorylation, which will inhibit the lipid synthesis in
the liver. Lastly, the current study reported that enhanced Nrf2
activity increased response upon insulin administration and
glucose tolerance ability. Overall, the Nrf2-Keap1 pathway has
a role in regulating lipid metabolism during fasting.
Supporting Information
Figure S1.  Representative pictures of hematoxylin and
eosin staining of livers sections from C57BL/6 and Keap1-
KD upon fasting. C57BL/6 (WT) and Keap1-KD (KD) mice
fasted for 24 hrs. Part of liver tissue was fixed with 10%
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formalin. Liver sections were cut (5 μm) and hematoxylin and
eosin staining was performed. Scale bar = 100 μm.
(TIF)
Figure S2.  Expression of lipase in white adipose tissue of
fed and fasted C57BL/6 and Keap1-KD mice. C57BL/6 (WT)
and Keap1-KD (KD) mice fasted for 24 hrs. Epididymal WAT
was harvested and total RNA was extracted by Trizol. The
target genes mRNA levels were determined by quantitative
real-time PCR. The relative mRNA levels has been normalized
with β-2 microglobulin. *, P<0.05, WT-fed vs. WT-fasted.
(TIF)
Figure S3.  Insulin tolerance test on C57BL/6 and Keap1-
KD mice. Twenty-week-old C57BL/6 (WT) and Keap1-KD (KD)
fasted for 6 hrs were injected with insulin (1U/kg body weight)
intraperitoneally. Blood glucose was determined by tails bleeds
at 0, 15, 30, 60, and 120 mins post insulin administration.
(TIF)
Table S1.  List of primers sequence used.
(DOC)
Table S2.  Serum cytokine content in C57BL/6 and Keap1-
KD mice after 24 hours fasting.
(DOCX)
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